NCT01561690已完成2 期
A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of ARRY-502 in Adults With Persistent Asthma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 184
- 试验地点
- 42
- 主要终点
- Assess the efficacy of the study drug (versus placebo) in terms of prebronchodilator forced expiratory volume in 1 second (FEV1).
研究概览
简要总结
This is a Phase 2 study, involving a 6-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-502 in treating mild to moderate persistent asthma, and to further evaluate the safety of the drug. Approximately 180 patients from the US will be enrolled in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented history of bronchial asthma diagnosed at least 6 months prior to study start and prior to the age of 40 years.
- •Body mass index (BMI) of 18 to 35 inclusive.
- •An ACQ score of ≥ 1.5 at specified time points prior to first dose of study drug.
- •A best prebronchodilator FEV1 of 60% to 85% of the predicted normal value and a change in best postbronchodilator FEV1 of ≥ 12% and ≥ 200 mL at specified time points prior to first dose of study drug.
- •Additional criteria exist.
排除标准
- •Evidence of aspirin-sensitive asthma.
- •Pre-existing lung disease other than asthma.
- •Clinically significant dermatologic, hematological, renal, endocrine, pulmonary (other than asthma), gastrointestinal, cardiovascular, hepatic, neurologic, ophthalmologic, musculoskeletal or immunologic disease (excepting allergic disease and asthma) that is uncontrolled despite treatment or is likely in the opinion of the Investigator to require a change in therapy during the study.
- •Patients with any current or past history of cancer within 5 years prior to study start except for treated basal cell or squamous cell carcinomas of the skin, ductal carcinoma in situ of the breast or cervical carcinomas in situ.
- •Any history of serious illness requiring hospitalization within 6 months prior to study start.
- •Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.
- •A positive test for drugs or alcohol, unless the positive drug screen is associated with a prescribed medication and is approved by the Medical Monitor.
- •Smoking (tobacco or marijuana) within 6 months prior to study start and/or a smoking history of > 10 packs/year.
- •Blood donation of ≥ 1 pint (473 mL) within 8 weeks prior to the first dose of study drug.
- •Previous treatment with ARRY-
- •Additional criteria exist.
研究组 & 干预措施
ARRY-502
Experimental
干预措施: ARRY-502, CRTh2 antagonist; oral (Drug)
Placebo
Placebo Comparator
干预措施: Placebo; oral (Drug)
结局指标
主要结局
Assess the efficacy of the study drug (versus placebo) in terms of prebronchodilator forced expiratory volume in 1 second (FEV1).
时间窗: 6 weeks
次要结局
- Measure the exposure of study drug in terms of plasma concentrations.(6 weeks)
- Assess the effect of study drug on respiratory function in terms of FEV1, forced vital capacity (FVC), forced expiratory flow (FEF) and peak expiratory flow (PEF).(6 weeks)
- Assess the effect of study drug on asthma control in terms of Asthma Control Questionnaire (ACQ) score, the number of symptom-free days and the number of weekly short-acting beta (ß) 2 agonist (SABA) metered dose inhaler (MDI) actuations.(6 weeks)
- Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms.(6 weeks)
研究者
研究点 (42)
Loading locations...
相似试验
招募中
2 期
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisNon-cystic Fibrosis BronchiectasisNCT06559150Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA284
已完成
2 期
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular DiseaseMild to Moderate Dementia Due to Alzheimer's DiseaseWith or Without Coexisting Cerebrovascular DiseaseNCT03462121Regenera Pharma Ltd83
已完成
2 期
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)Hypertension, PulmonaryNCT04945460Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA164
终止
2 期
LYT-100 in Patients With BCRLBreast Cancer Related LymphoedemaLymphoedemaNCT04243837PureTech50
招募中
2 期
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)NCT05090891Incyte Corporation98